Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, ...

Glucopilot dynamic dosing algorithm was associated with improved glycemic control especially among subgroups with ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

Thyroid cancer burden attributable to high BMI was increasing between 1990 and 2021 in the US, especially among men and older ...

Adolescents with PCOS demonstrated comparable weight loss to their reproductively normal peers after undergoing bariatric ...

Adrenal adenomas were associated with attenuated weight loss among patients with obesity or overweight using GLP-1 or GIP/GLP ...

Diazoxide choline extended-release tablets demonstrated favorable safety profile across 4 years among patients with Prader-Willi Syndrome.

Veligrotug demonstrated significant improvements in proptosis, diplopia, and clinical activity score among patients with active thyroid eye disease.

COCPs were associated with improved obesity outcomes among patients with hyperandrogenic PCOS, but metformin added little ...

Crinecerfont is associated with sustained reductions in androstenedione and GC doses at 1 year in congenital adrenal hyperplasia.

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

PCOS was associated with an increased risk for vascular events including stroke among women with thrombotic disease, and a lower mean age.